← Leaderboards
Mark B. Feinberg
Emory University
$16,950,022
Attributed
$16,950,022
Total exposure
24
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $7M · FY2005–08$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
Funding mix
By agency
NIH$37,935,752 · 26
By mechanism
U19$25,083,545 · 3
P01$7,141,694 · 3
P51$2,917,191 · 18
R01$2,313,322 · 1
R21$480,000 · 1
Top collaborators
No co-investigators on record.
Most similar at Emory University
Same institution · by research overlap
- Guido Silvestri$61,186,493
- Francois J Villinger$61,853,654
- Aftab A. Ansari$22,344,206
- Rama Rao Amara$90,840,294
- James Gibson Else$12,717,755
Others in their field
Top investigators on “Aids Vaccines”
- Lawrence Corey · Fred Hutchinson Cancer Center$397,672,739
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$310,476,918
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$247,048,372
- Sharon A Nachman · Johns Hopkins University$210,246,546
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$193,500,790
- Judith S. Currier · University Of California Los Angeles$187,871,648
Research focus
Aids VaccinesVaccine DevelopmentVector VaccineMacaca MulattaCellular ImmunityAidsPrimatesAntigen PresentationVaccinesCytokineSimian Immunodeficiency VirusImmune ResponseImmunologyVirusCytotoxic T LymphocyteHuman Immunodeficiency VirusConsensusClinical Trials, Phase ICommunicable DiseasesAnimal ColonyLeukocyte Activation /TransformationHiv VaccineInflammationLymphatic System
Grant awards (54)
Core--Project Coordination and Product Development$1,037,718
U19 · FY2008 · AI · contact PI
Enhancing the Immunogenicity of Recombinant MVA Vectors$233,266
U19 · FY2008 · AI · contact PI
Optimizing the Immunogenicity of MVA-Based AIDS Vaccines$3,199,984
U19 · FY2007 · AI · contact PI
Core--Project Coordination and Product Development$1,657,367
U19 · FY2007 · AI · contact PI
Enhancing the Immunogenicity of Recombinant MVA Vectors$372,531
U19 · FY2007 · AI · contact PI
OPTIMIZE THE IMMUNOGENICITY OF MVA-BASED AIDS VACCINES$78,545
P51 · FY2007 · RR · contact PI
CELLULAR IMMUNE RESPONSES IN AIDS PATHOGENESIS$65,453
P51 · FY2007 · RR · contact PI
Optimizing the Immunogenicity of MVA-Based AIDS Vaccines$2,780,254
U19 · FY2006 · AI · contact PI
Project Coordination and Product Development$1,779,555
U19 · FY2006 · AI · contact PI
Enhancing the Immunogenicity of Recombinant MVA Vectors$400,014
U19 · FY2006 · AI · contact PI
OPTIMIZE THE IMMUNOGENICITY OF MVA-BASED AIDS VACCINES$59,665
P51 · FY2006 · RR · contact PI
CELLULAR IMMUNE RESPONSES IN AIDS PATHOGENESIS$59,665
P51 · FY2006 · RR · contact PI
Optimizing the Immunogenicity of MVA-Based AIDS Vaccines$4,202,132
U19 · FY2005 · AI
Project Coordination and Product Development$2,176,346
U19 · FY2005 · AI
Enhancing the Immunogenicity of Recombinant MVA Vectors$489,205
U19 · FY2005 · AI
NEW LIVE VIRAL VECTORS AS CANDIDATE AIDS VACCINES$62,838
P51 · FY2005 · RR
OPTIMIZE THE IMMUNOGENICITY OF MVA-BASED AIDS VACCINES$52,438
P51 · FY2005 · RR
CELLULAR IMMUNE RESPONSES IN AIDS PATHOGENESIS$52,438
P51 · FY2005 · RR
Optimizing the Immunogenicity of MVA-Based AIDS Vaccines$4,133,290
U19 · FY2004 · AI
Project Coordination and Product Development$2,140,692
U19 · FY2004 · AI
Enhancing the Immunogenicity of Recombinant MVA Vectors$481,191
U19 · FY2004 · AI
T LYMPHOCYTE POPULATION DYNAMICS AND AIDS PATHOGENESIS$62,031
P51 · FY2004 · RR
NEW LIVE VIRAL VECTORS AS CANDIDATE AIDS VACCINES$62,031
P51 · FY2004 · RR
NOVEL METHOD TO EVALUATE HIV-SPECIFIC CTL RESPONSES$62,031
P51 · FY2004 · RR
CENTER FOR AIDS RESEARCH$62,031
P51 · FY2004 · RR
CELLULAR IMMUNE RESPONSES IN AIDS PATHOGENESIS$51,707
P51 · FY2004 · RR
NEW LIVE VIRAL VECTORS AS CANDIDATE AIDS VACCINES$1,832,252
P01 · FY2003 · AI
CENTER FOR AIDS RESEARCH$1,296,815
P51 · FY2003 · RR
Cellular Immune Responses and AIDS Pathogenesis$808,621
R01 · FY2003 · AI
T LYMPHOCYTE POPULATION DYNAMICS AND AIDS PATHOGENESIS$56,815
P51 · FY2003 · RR
NEW LIVE VIRAL VECTORS AS CANDIDATE AIDS VACCINES$56,815
P51 · FY2003 · RR
NOVEL METHOD TO EVALUATE HIV-SPECIFIC CTL RESPONSES$56,815
P51 · FY2003 · RR
CELLULAR IMMUNE RESPONSES IN AIDS PATHOGENESIS$47,395
P51 · FY2003 · RR
NEW LIVE VIRAL VECTORS AS CANDIDATE AIDS VACCINES$1,616,957
P01 · FY2002 · AI
Cellular Immune Responses and AIDS Pathogenesis$758,626
R01 · FY2002 · AI
NOVEL METHOD TO EVALUATE HIV-SPECIFIC CTL RESPONSES$240,000
R21 · FY2002 · AI
AIDS RESEARCH T LYMPHOCYTE POPULATION DYNAMICS &AIDS PATHOGENESIS$209,143
P51 · FY2002 · RR
HIV VACCINES FOR CHILDREN &ADOLESCENTS$209,143
P51 · FY2002 · RR
CORE--DATA MANAGEMENT FACILITY$0
P01 · FY2002 · AI
ENHANCING THE MAGNITUDE AND LONGEVITY OF VACCINE INDUCED IMMUNE RESPONSES$0
P01 · FY2002 · AI
NEW LIVE VIRAL VECTORS AS CANDIDATE AIDS VACCINES$1,479,558
P01 · FY2001 · AI
Cellular Immune Responses and AIDS Pathogenesis$746,075
R01 · FY2001 · AI
New Live Viral Vectors as Candiate AIDS Vaccines$282,400
P01 · FY2001 · AI
NOVEL METHOD TO EVALUATE HIV-SPECIFIC CTL RESPONSES$240,000
R21 · FY2001 · AI
CORE--DATA MANAGEMENT FACILITY$0
P01 · FY2001 · AI
CORE--DATA MANAGEMENT FACILITY$0
P01 · FY2001 · AI
ENHANCING THE MAGNITUDE AND LONGEVITY OF VACCINE INDUCED IMMUNE RESPONSES$0
P01 · FY2001 · AI
ENHANCING THE MAGNITUDE AND LONGEVITY OF VACCINE INDUCED IMMUNE RESPONSES$0
P01 · FY2001 · AI
NEW LIVE VIRAL VECTORS AS CANDIDATE AIDS VACCINES$1,458,903
P01 · FY2000 · AI
CORE--DATA MANAGEMENT FACILITY$235,812
P01 · FY2000 · AI
ENHANCING THE MAGNITUDE AND LONGEVITY OF VACCINE INDUCED IMMUNE RESPONSES$235,812
P01 · FY2000 · AI
RESEARCH T LYMPHOCYTE POPULATION DYNAMICS &AIDS PATHOGENESIS$84,459
P51 · FY2000 · RR
NEW LIVE VIRAL VECTORS AS CANDIDATE AIDS VACCINES$84,459
P51 · FY2000 · RR
HIV VACCINES FOR CHILDREN AND ADOLESCENTS$84,459
P51 · FY2000 · RR